top of page
Treating Cancer With Precision
News
Categories
Sign up
Featured Posts
Archive
Follow Us
Jun 8, 2022
FDA Approval of IDE to Initiate Multi-Center Pivotal Study of Alpha DaRT™ in Recurrent Cutaneous SCC
JERUSALEM, June 8, 2022 -- Alpha Tau Medical Ltd. (Nasdaq: DRTS and DRTSW), ("Alpha Tau" or the "Company"), the developer of the...
Jun 8, 2022
Alpha Tau Announces Resignation of Gary Leibler from its Board of Directors
JERUSALEM, June 7, 2022 -- Alpha Tau Medical Ltd. (Nasdaq: DRTS) (Nasdaq: DRTSW), ("Alpha Tau" or the "Company"), the developer of the...
May 26, 2022
Alpha Tau Medical Announces First Quarter 2022 Financial Results and Provides Corporate Update
-Debuted as publicly-traded oncology company in March 2022 under symbol DRTS while raising approximately $104 million in gross proceeds-...
Mar 28, 2022
Alpha Tau Medical Announces Full Year 2021 Financial Results and Provides Corporate Update
-Debuted as publicly-traded oncology company in March 2022 under symbol DRTS while raising approximately $90 million in gross proceeds-...
Mar 22, 2022
Alpha Tau Medical Ltd. Appoints Ruth Alon to its Board of Directors
JERUSALEM, March 21, 2022 -- Alpha Tau Medical Ltd. (Nasdaq: DRTS), the developer of the innovative alpha-radiation cancer therapy Alpha...
Mar 8, 2022
Alpha Tau Medical and Healthcare Capital Corp. Announce Completion of Business Combination
Alpha Tau Is Expected to Commence Trading on Nasdaq Under the Ticker "DRTS" on March 8, 2022 JERUSALEM and WILMINGTON, Del., March 7,...
Jan 20, 2022
New Alpha DaRT Research Collaboration on Immune Stimulation in the Treatment of Breast Cancer
JERUSALEM, Jan 20, 2022 – Alpha Tau Medical Ltd. (“Alpha Tau”), the developer of the innovative alpha-radiation cancer therapy Alpha...
Jan 10, 2022
Results of First US Clinical Trial of Alpha DaRT™
Alpha Tau Announces Results of First US Clinical Trial of Alpha DaRT™ in Malignant Skin & Soft Tissue Cancers, Showing Complete Response...
Jan 3, 2022
Completion of Enrollment of Japanese Pivotal Clinical Trial in Recurrent Head & Neck Cancer
JERUSALEM, Dec. 31, 2021 -- Alpha Tau Medical Ltd. ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha...
Nov 4, 2021
Enrollment of First Patient in Combination Trial of Alpha DaRT™ and Pembrolizumab (Keytruda®)
JERUSALEM, Nov. 3, 2021 -- Alpha Tau Medical Ltd. ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha...
bottom of page